

SimcereZaiming showcases latest R&D progressed on its debut at ASCO as 6 studies regarding 3 products published at ASCO

Simcere Zaiming, an innovative oncology-focused biopharma and a subsidiary of Simcere Pharmaceutical Group, exhibited a booth at ASCO for the first time.

BOSTON, MASSACHUSETTS, THE UNITED STATES, June 7, 2023 /EINPresswire.com/ -- The annual meeting of the American Society of Clinical Oncology (ASCO) 2023, one of the most prestigious clinical academic events in oncology, is being held in Chicago, USA on June 2-6. Simcere Zaiming, an innovative oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group, exhibited a booth at ASCO for the first time. The Zaiming team held on-site meetings with clinicians from around the world to discuss the progress being made by the company by showcasing the latest he research and development of the company's innovative anti-tumor drugs.

A total of six relevant studies regarding three innovative drugs in Zaiming's product portfolio, COSELA®, Enweida® and Endostar®, have published the latest clinical progress in the form of posters and abstracts. Among them, there are clinical trials initiated by Chinese and foreign investigators (IIT), real-world studies (RWS), and registration studies promoted by Zaiming collaborative innovation partners, involving small cell lung cancer,



Bijoyesh Mookerjee M.D., CMO of Simcere Zaiming left 4 held pleasant conversation with visitors at Zaiming's booth

Preclinical	IND enabling	Phase 1a	Phase 1b/2	Pivotal/Phase III	NDA and post marketing
SIM 0618	SIM 0602	SIM 0500 Multiple myeloma	SERD HR + Breast Cancer	Docetaxel micelles Solid tumor	COSELA® Triple negative breast cancer
SIM 0512	SIM 0526	SIM 0501 Solid tumor	TNFR2 Solid tumor&CTLC	Enweida® + Suvenctug Solid tumor	Suvenctug Platinum-resistant ovarian cancer
SIM 0612	SIM 0508	SIM 0502 Solid tumor	PRMT5 Solid tumor	Enweida® + Lenvatinib Endometrial cancer	Endostar® Malignant pleural and peritoneal effusion
SIM 0552	SIM 0606	SIM 0503 Solid tumor	PD-L1/IL15v Solid tumor		Paxalisib Glioblastoma
SIM 0520	SIM 0510	SIM 0505 Solid tumor	TIGIT/PVRIG Solid tumor		
SIM 0686	SIM 0528	SIM 0506 Solid tumor	CD80/IL2 Solid tumor		
SIM 0558	SIM 0682				
SIM 0620					

■ Innovative monoclonal antibody ■ Bi/multi specific antibody drug
■ ADC drug ■ Small molecule drug
⚙️ Global Development ☑️ Advancing by partner

Zaiming showcased the company's innovative R&D pipeline at ASCO Booth

non-small cell lung cancer, triple-negative breast cancer, gastric cancer, soft tissue sarcoma, and other cancer types. Congratulations to the Zaiming team!

COSELA® (trilaciclib) is an innovative bone marrow protection drug to be used prior to chemotherapy, developed by Simcere Pharmaceutical Co., Ltd. in cooperation with G1 Therapeutics of the United States. COSELA has been approved for marketing in China and the United States. Simcere Zaiming has the rights and interests of all indications of this product in Greater China

01 Real world outcomes of trilaciclib in ES-SCLC

Abstract No.: e20637

Author: Joseph Elijah et al., Roswell Park Comprehensive Cancer Center

<https://meetings.asco.org/abstracts-presentations/223649>

02 Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune data from a phase 2 study

Abstract No.: 603

Poster No.: 433

Author: Jeremy Meyer Force et al., Duke University School of Medicine

<https://meetings.asco.org/abstracts-presentations/223763>

Enweida® (Envafolimab) is an innovative subcutaneous injection PD-L1 antibody tumor drug from Simcere Pharmaceutical Group in strategic cooperation with 3Dmed and Alphamab, and Simcere Zaiming is responsible for the exclusive commercial promotion of the product in mainland China

01 First-line envafolimab plus SOX chemotherapy for PD-L1 positive metastatic or recurrent gastric adenocarcinoma: A multi-centre, single-arm phase II clinical trial.

Abstract No.: e16029

Author: Zhu Liangjun, Jiangsu Cancer Hospital

<https://meetings.asco.org/abstracts-presentations/222055>

02 ENVASARC: A pivotal trial of envafolimab and envafolimab in combination with ipilimumab in patients with advanced or metastatic unpleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

Abstract No.: TPS11583

Poster No.: 515a

Author: Richard F. Riedel et al. Duke Cancer Institute, Duke University Medical Center

<https://meetings.asco.org/abstracts-presentations/226102>

Endostar® (recombinant human endostatin) is a Simcere and then Lumenis product, a angiogenesis inhibitor

01 Endostatin in combination with PD-1 antibody plus chemotherapy as first-line regimen for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer: A real-world study
Abstract No.: e20564

Author: Zhang Guoqing, et al., First Medical Center, Chinese PLA General Hospital

<https://meetings.asco.org/abstracts-presentations/223582>

02 Immunotherapy combined with rh-endostatin improved clinical outcomes over ICIs plus chemotherapy for second-line treatment of advanced NSCLC.

Abstract No.: e21133

Author: Hongxiang Huang et al., Department of Oncology, the First Affiliated Hospital of Nanchang University

<https://meetings.asco.org/abstracts-presentations/219073>

About Simcere Zaiming

Simcere Zaiming is a pharmaceutical company specializing in oncology, and a subsidiary of Simcere Pharmaceutical Group Limited, that focuses on the R&D, production and commercialization of innovative cancer therapeutics. The company was formed in 2023 and is committed to solving unmet clinical needs for cancer patients in China and around the world by developing breakthrough treatments. Simcere Zaiming has an innovative R&D pipeline with differentiated clinical value, among which 15 assets are currently in clinical trials. In addition to the company's R&D portfolio, Simcere Zaiming is marketing three innovative drugs, COSELA[®], Endostar[®], and Envafohimab[®]. By collaborating with partners globally, Simcere Zaiming strives to bring potentially new innovative therapeutics to cancer patients worldwide.

Media Contact: pr@zaiming.com

Yiling Li

Simcere Zaiming Pharmaceutical Co.,Ltd.

+86 139 1475 7210

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/637901099>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.